However, primaquine can cause drug-induced haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, in addition to other side effects such as gastrointestinal disturbance and methaemoglobinaemia.4 Although concerns about haemolysis, coupled with a lack of available bedside G6PD testing, have prevented the widespread implementation of primaquine radical cure,5 point of care G6PD testing is increasingly available, with a quantitative test now approved in India, paving the way for safer use of primaquine.6 The gene discussed is G6PD; the disease is G6PD deficiency.